atezolizumab | MediPaper Medical Communications Ltd.

Posts

Atezolizumab FDA approved for PD-L1 positive unresectable triple-negative breast cancer

9th March 2019/0 Comments/in Breast Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On 8 March 2019, the FDA granted accelerated approval to atezolizumab (Tecentriq®, Genentech/Roche) in combination with albumin-bound paclitaxel (nab-paclitaxel) for the treatment of adult unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) patients with programmed death 1 ligand (PD-L1) stained tumour-infiltrating immune cells (IC) of any intensity covering ≥1% of the tumour area, as determined by the VENTANA PD-L1 (SP142) Assay companion diagnostic (CDx).

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

US FDA approved immune-checkpoint inhibitors updated 09-Mar-2019

9th March 2019/17 Comments/in AE Management, Gastrointestinal Cancer, Genitourinary Cancer, Gynaecological Cancer, Haematology, Head and Neck Cancer, ImmunoOncology, Immunotherapy, irAE Management, Lung Cancer, Melanoma & Skin Cancer, Oncology /by News Feed

Know all the United States Food and Drug Administration (U.S. FDA) approved immune-checkpoint inhibitors. Members of MediPaper can download the free PPT slides summarising the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

11th December 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies, US FDA Onc\Haem Approvals /by News Feed

On 6 December 2018, the FDA approved atezolizumab (Tecentriq®, Roche/Genentech) plus bevacizumab and chemotherapy with paclitaxel and carboplatin for the frontline treatment of metastatic non-squamous non-small cell lung cancer (NSq NSCLC) patients not harbouring any EGFR or ALK genomic tumour aberrations.

innovent biologics anti-pd1 sintilimab plus biosimilar bevacizumab receive ind status by china nmpa

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

15th October 2018/0 Comments/in Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Medical News Asia, Oncology, Targeted Therapies /by News Feed

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ — The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

IMpower133 first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11th October 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by News Feed

Atezolizumab (Tecentriq®, Roche/Genentech) plus standard chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) was associated with a significantly longer overall survival (OS) and progression-free survival (PFS) when compared with chemotherapy alone.

Front-line atezolizumab plus chemotherapy improves PFS in NSCLC

Frontline atezolizumab plus chemotherapy improves PFS in NSCLC

25th September 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, WCLC 2018 /by News Feed

An interim analysis of the Phase III IMpower132 study showed that atezolizumab (Tecentriq®, Roche/Genentech) plus platinum-based chemotherapy (cisplatin or carboplatin) with pemetrexed improves the median progression-free survival (PFS) in treatment-naïve patients with non-squamous non-small cell lung cancer (NSCLC). The median PFS for atezolizumab plus pemetrexed and a platinum salt was 7.6 months vs 5.2 months with chemotherapy alone (HR=0.60, 95% CI: 0.49-0.72; p<0.0001).

Blood-based TMB-assay predicts response to atezolizumab in NSCLC patients

Plasma TMB predicts response to atezolizumab in NSCLC patients

31st August 2018/0 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Pathology, Translational Research /by News Feed

A high tumour mutational burden in the plasma (bTMB) is a clinically actionable biomarker for atezolizumab (Tencentriq®, Roche) treatment in patients who failed 1st-line platinum-based therapy for advanced non-small cell lung cancer (NSCLC).

Nivolumab FDA approved for patients with metastatic small cell lung cancer (SCLC)

Pembrolizumab and atezolizumab USPIs updated by FDA

21st August 2018/1 Comment/in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, US FDA Onc\Haem Approvals /by News Feed

On the 16th of August, 2018, the FDA updated the prescribing information for pembrolizumab (Keytruda®, Merck) and atezolizumab (Tecentriq®, Roche/Genentech) and added the requirement for the use of an FDA-approved companion diagnostic test (CDx) to determine PD-L1 levels in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

ASCO 2018 nsclc immunotherapy ASCO18 lung cancer pembrolizumab avelumab nivolumab duravalumab ipilimumab osimertinib dacomitinib lorlatinib crizotinib alectinib keytruda KEYNOTE CheckMate JAVELIN IMpower

©eraxion / 123RF Stock Photo

ASCO 2018 NSCLC: The ASCO18 Lung Cancer Track Summarised

25th June 2018/5 Comments/in ASCO 2018 Annual Meeting, Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Targeted Therapies /by Anne John Michael

Non-small cell lung cancer (NSCLC): a key feature of the American Society of Clinical Oncology (ASCO) 2018 annual meeting. This year, encouraging results with single-agent immunotherapy (I-O) and combinations of I-O with chemotherapy (CTx), including the CheckMate 227 with nivolumab (NIVO), IMpower131 and IMpower150 studies with atezolizumab (ATEZO), and KEYNOTE-042 and KEYNOTE-407 studies with pembrolizumab (PEMBRO). Furthermore, important Asian data on treatments for epidermal growth-factor recptor (EGFR) mutation-positive (mu+) NSCLC (ARCHER 1050, NEJ009, NEJ026, and JO25567).

FDA has limited the use of Tecentriq and Keytruda for patients with locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing therapy. More Information. June 19, 2018

FDA limits use of atezolizumab and pembrolizumab in urothelial carcinoma

19th June 2018/1 Comment/in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Oncology, Translational Research, US FDA Onc\Haem Approvals /by News Feed

On June 19, the FDA limited the use of atezolizumab and pembrolizumab for the treatment of locally advanced or metastatic urothelial cancer patients ineligible for cisplatin-containing therapy.

ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2

© krishnacreations / 123RF Stock Photo

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

10th June 2018/3 Comments/in ASCO 2018 Annual Meeting, Chemotherapy, Conferences, Gastrointestinal Cancer, ImmunoOncology, Immunotherapy, Oncology, Targeted Therapies, Translational Research /by Anne John Michael

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

Ribociclib FDA label updated to include pre- and perimenopausal women

©United States Food and Drug Agency

FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression

18th May 2018/2 Comments/in US FDA Onc\Haem Approvals /by Stijn van den Borne, MSc

On May 18, the United States (US) Food and Drug Administration (FDA) issued an alert about the decreased survival in studies with pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) as single agent first-line therapy for patients with metastatic urothelial cancer (mUCC) and low expression of the programmed death ligand 1 (PD-L1) protein.

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

10th May 2018/3 Comments/in Chemotherapy, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology, Translational Research /by Stijn van den Borne, MSc

First-line atezolizumab plus bevacizumab, carboplatin and paclitaxel improves PFS in patients with non-squamous NSCLC. Two presentations on the IMPower150 study by Martin Reck (ELCC 2018) and Mark Socinski (AACR 2018) discussed the frontline addition of atezolizumab to bevacizumab and chemotherapy in different lung cancer subgroups (NCT02366143).

Making sense of immunotherapy in NSCLC

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

26th March 2018/5 Comments/in Guidelines, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by Stijn van den Borne, MSc

The expansion of therapeutic options with immunotherapies will reflect a dramatic change in the guidelines for lung cancer, where immunotherapies mostly compete with the use of chemotherapeutic agents. A brief communication on immunotherapies for NSCLC.

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

26th October 2016/Enter your password to view comments./in Gastrointestinal Cancer, Genitourinary Cancer, Haematology, Head and Neck Cancer, ImmunoOncology, Lung Cancer, Melanoma & Skin Cancer, Pathology, Translational Research /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data – Download the PPT

9th October 2016/Enter your password to view comments./in Conferences, Genitourinary Cancer, ImmunoOncology, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

2nd June 2016/Enter your password to view comments./in Genitourinary Cancer, ImmunoOncology, Immunotherapy, Lung Cancer, Oncology /by Stijn van den Borne, MSc

There is no excerpt because this is a protected post.

Therapeutic Areas